Business Context and Reporting Period
Compugen Ltd. (NASDAQ: CGEN), a drug and diagnostic discovery company based in Tel-Aviv, Israel, filed this Form 6-K for the month of July 2003. The filing incorporates two press releases: one dated July 17, 2003, regarding the transfer of the Bioccelerator product line, and another dated July 23, 2003, reporting financial results for the second quarter ended June 30, 2003.
Key Financial Metrics
Second Quarter 2003 (Three Months Ended June 30, 2003):
- Total Revenues: $2.9 million (including $382,000 in R&D grants).
- Net Loss: $2.4 million ($0.09 per share), including a $94,000 non-cash charge for amortization of deferred compensation.
- Operating Loss: $3.0 million.
- Liquidity: As of June 30, 2003, the company held $64.7 million in cash, cash equivalents, and marketable securities.
First Six Months 2003 (Six Months Ended June 30, 2003):
- Total Revenues: $5.5 million (including $837,000 in R&D grants).
- Net Loss: $4.7 million ($0.18 per share), including a $188,000 non-cash charge for amortization of deferred compensation.
- Operating Loss: $6.0 million.
Balance Sheet Highlights (June 30, 2003):
- Total Assets: $74.2 million.
- Total Liabilities: $9.7 million (including $2.0 million in convertible loans).
- Shareholders' Equity: $64.6 million.
Material Changes Versus Prior Period
Revenue: Q2 2003 revenues increased slightly to $2.9 million from $2.8 million in Q2 2002. However, R&D grants decreased to $382,000 from $472,000 in the prior year period. For the first six months, revenues decreased slightly to $5.5 million from $5.6 million in 2002.
Profitability: The net loss improved significantly. Q2 2003 net loss was $2.4 million compared to $2.8 million in Q2 2002. For the first six months, the net loss was $4.7 million compared to $6.0 million in the same period of 2002. This improvement was largely driven by a reduction in the amortization of deferred compensation ($94,000 in Q2 2003 vs. $403,000 in Q2 2002).
Expenses: Research and development expenses increased to $3.4 million in Q2 2003 from $3.0 million in Q2 2002. Sales and marketing expenses decreased to $1.1 million from $1.3 million.
Liquidity: Cash and marketable securities decreased by $2.6 million from $67.3 million as of March 31, 2003, to $64.7 million as of June 30, 2003.
Guidance, Outlook, and Material Events
Bioccelerator Transfer: On July 17, 2003, Compugen announced the transfer of its Bioccelerator product line to Biocceleration Ltd. The transaction involves fixed payments over approximately two years and royalties on future sales. The transfer is expected to be completed by the end of August 2003. Management stated this move strengthens the company's focus on high-end platforms/services for biopharmaceutical companies and internal research discoveries.
Management Commentary: CEO Mor Amitai highlighted continued investment in predictive discovery capabilities, citing discoveries in alternative splicing and natural antisense in the human genome, as well as potential therapeutic proteins (PSA and VEGF splice variants). The company uses three criteria for selecting therapeutic proteins: relation to existing drugs, reliance on proprietary technology for discovery, and higher probability of success compared to existing compounds.
Risks: The filing includes standard forward-looking statement disclaimers. Identified risks include changes in collaborator relationships, competitive products, technological changes, new product development risks, and customer retention.
Investor Verification Checklist
- Verify the final terms and closing date of the Bioccelerator product line transfer to Biocceleration Ltd.
- Confirm the sustainability of the reduction in deferred compensation amortization charges in future quarters.
- Monitor the trend in R&D grants, which decreased in both Q2 and the first six months of 2003 compared to the prior year.
- Assess the progress of internal discovery projects, specifically the PSA and VEGF splice variants mentioned by management.
- Review the impact of the $2.0 million convertible loan on future liquidity and capital structure.